Inventor · disambiguated record
David M. Valenzuela
Also filed as: VALENZUELA DAVID · VALENZUELA DAVID M
92 granted patents·27 pending applications·2,517 citations·filing 1988–2024
99Inventor score
Files withREGENERON PHARMA104ECONOMIDES ARIS N3FRENDEWEY DAVID2MURPHY ANDREW J2ONCOGENE SCIENCE INC2
Top patents by PatentIndex Score
119 records- 0199US9546384B2Methods and compositions for the targeted modification of a mouse genomeREGENERON PHARMA·Filed 2014·Granted Jan 17, 2017·31 cites·26 claims
- 0299US9228208B2Methods and compositions for the targeted modification of a genomeREGENERON PHARMA·Filed 2014·Granted Jan 5, 2016·79 cites·24 claims
- 0399US7205148B2Genome mutation by intron insertion into an embryonic stem cell genomeREGENERON PHARMA·Filed 2004·Granted Apr 17, 2007·93 cites·9 claims
- 0499US6586251B2Methods of modifying eukaryotic cellsREGENERON PHARMA·Filed 2000·Granted Jul 1, 2003·505 cites·14 claims
- 0598US10385359B2Targeted modification of rat genomeREGENERON PHARMA·Filed 2017·Granted Aug 20, 2019·29 cites·39 claims
- 0698US10329582B2Genetic modification of ratsREGENERON PHARMA·Filed 2016·Granted Jun 25, 2019·25 cites·37 claims
- 0798US10208317B2Methods and compositions for the targeted modification of a mouse embryonic stem cell genomeREGENERON PHARMA·Filed 2016·Granted Feb 19, 2019·15 cites·61 claims
- 0898US8791323B2Hybrid antibodies comprising human variable regions and mouse constant regions produced in a genetically modified mouseMURPHY ANDREW J·Filed 2006·Granted Jul 29, 2014·97 cites·3 claims
- 0998US8697851B2MiRNA-regulated differentiation-dependent self-deleting cassetteREGENERON PHARMA·Filed 2012·Granted Apr 15, 2014·91 cites·9 claims
- 1098US8354389B2miRNA-regulated differentiation-dependent self-deleting cassetteREGENERON PHARMA·Filed 2010·Granted Jan 15, 2013·56 cites·13 claims
- 1198US7659442B2Method for making homozygous genetic modificationsREGENERON PHARMA·Filed 2007·Granted Feb 9, 2010·239 cites·18 claims
- 1298US7576259B2Method for making genetic modificationsREGENERON PHARMA·Filed 2007·Granted Aug 18, 2009·236 cites·18 claims
- 1398US7294754B2Method for generating an animal homozygous for a genetic modificationREGENERON PHARMA·Filed 2005·Granted Nov 13, 2007·445 cites·15 claims
- 1497US9730434B2Methods and compositions for generating a mouseREGENERON PHARMA·Filed 2016·Granted Aug 15, 2017·11 cites·27 claims
- 1597US8759105B2Method for genetically modifying mouse embryonic stem cell by homologous recombinationECONOMIDES ARIS N·Filed 2007·Granted Jun 24, 2014·40 cites·10 claims
- 1696US10301646B2Nuclease-mediated targeting with large targeting vectorsREGENERON PHARMA·Filed 2017·Granted May 28, 2019·12 cites·28 claims
- 1796US10039269B2Methods and compositions for generating a mouseREGENERON PHARMA·Filed 2017·Granted Aug 7, 2018·10 cites·21 claims
- 1896US8846402B2Method for genetically modifying isolated non-human mammalian cell by homologous recombinationREGENERON PHARMA·Filed 2012·Granted Sep 30, 2014·17 cites·54 claims
- 1996US8518392B2Promoter-regulated differentiation-dependent self-deleting cassetteFRENDEWEY DAVID·Filed 2010·Granted Aug 27, 2013·57 cites·11 claims
- 2095US10711280B2Methods and compositions for the targeted modification of a mouse ES cell genomeREGENERON PHARMA·Filed 2018·Granted Jul 14, 2020·5 cites·69 claims
- 2195US9738897B2Nuclease-mediated DNA assemblyREGENERON PHARMA·Filed 2015·Granted Aug 22, 2017·13 cites·29 claims
- 2295US9708635B2Methods of making a nucleic acid encoding a human variable regionREGENERON PHARMA·Filed 2012·Granted Jul 18, 2017·9 cites·10 claims
- 2395US9414575B2Methods and compositions for generating a mouseREGENERON PHARMA·Filed 2014·Granted Aug 16, 2016·12 cites·25 claims
- 2494US10640800B2Mice that produce hybrid antibodiesREGENERON PHARMA·Filed 2016·Granted May 5, 2020·4 cites·6 claims
- 2594US9834786B2Nuclease-mediated targeting with large targeting vectorsREGENERON PHARMA·Filed 2013·Granted Dec 5, 2017·13 cites·34 claims
- 2694US9388446B2Methods of producing hybrid antibodiesREGENERON PHARMA·Filed 2013·Granted Jul 12, 2016·6 cites·8 claims
- 2794US8946505B2Promoter-regulated differentiation-dependent self-deleting cassetteREGENERON PHARMA·Filed 2013·Granted Feb 3, 2015·10 cites·11 claims
- 2894US8946504B2Promoter-regulated differentiation-dependent self-deleting cassetteREGENERON PHARMA·Filed 2013·Granted Feb 3, 2015·10 cites·16 claims
- 2993US10975390B2Targeted modification of rat genomeREGENERON PHARMA·Filed 2019·Granted Apr 13, 2021·4 cites·46 claims
- 3093US9580715B2Nuclease-mediated DNA assemblyREGENERON PHARMA·Filed 2015·Granted Feb 28, 2017·7 cites·30 claims
- 3193US9353394B2Methods of producing hybrid antibodiesREGENERON PHARMA·Filed 2013·Granted May 31, 2016·6 cites·7 claims
- 3292US9528136B2Methods of modifying eukaryotic cellsREGENERON PHARMA·Filed 2013·Granted Dec 27, 2016·5 cites·9 claims
- 3392US9371553B2Genetically modified mice that produce hybrid antibodiesREGENERON PHARMA·Filed 2013·Granted Jun 21, 2016·6 cites·5 claims
- 3492US9267152B2MiRNA-regulated differentiation-dependent self-deleting cassetteREGENERON PHARMA·Filed 2015·Granted Feb 23, 2016·4 cites·29 claims
- 3591US10457960B2Methods and compositions for targeted genetic modification using paired guide RNAsREGENERON PHARMA·Filed 2015·Granted Oct 29, 2019·5 cites·53 claims
- 3691US10378040B2Mice that produce hybrid antibodiesREGENERON PHARMA·Filed 2013·Granted Aug 13, 2019·4 cites·4 claims
- 3791US10344299B2Compositions and methods for modifying cellsREGENERON PHARMA·Filed 2017·Granted Jul 9, 2019·3 cites·13 claims
- 3891US10106820B2Methods and compositions for modifying a targeted locusREGENERON PHARMA·Filed 2015·Granted Oct 23, 2018·6 cites·43 claims
- 3991US9902971B2Methods for producing a mouse XY embryonic (ES) cell line capable of producing a fertile XY female mouse in an F0 generationREGENERON PHARMA·Filed 2015·Granted Feb 27, 2018·5 cites·41 claims
- 4091US8816150B2Conditioned culture mediaPOUEYMIROU WILLIAM·Filed 2007·Granted Aug 26, 2014·14 cites·19 claims
- 4190US10793874B2Methods and compositions for targeted genetic modifications and methods of useREGENERON PHARMA·Filed 2018·Granted Oct 6, 2020·4 cites·13 claims
- 4290US9376699B2Methods of producing hybrid antibodiesMURPHY ANDREW J·Filed 2011·Granted Jun 28, 2016·4 cites·8 claims
- 4390US9096870B2miRNA-regulated differentiation-dependent self-deleting cassetteREGENERON PHARMA·Filed 2014·Granted Aug 4, 2015·6 cites·13 claims
- 4489US10781453B2Non-human animals having a hexanucleotide repeat expansion in a C9ORF72 locusREGENERON PHARMA·Filed 2017·Granted Sep 22, 2020·6 cites·48 claims
- 4589US10526630B2Genetically modified mice that produce hybrid antibodiesREGENERON PHARMA·Filed 2013·Granted Jan 7, 2020·3 cites·2 claims
- 4689US10378037B2Methods of making a nucleic acid encoding a human variable regionREGENERON PHARMA·Filed 2013·Granted Aug 13, 2019·3 cites·10 claims
- 4789US10378039B2Mouse embryonic stem cells comprising a hybrid heavy chain immunoglobulin locusREGENERON PHARMA·Filed 2013·Granted Aug 13, 2019·3 cites·4 claims
- 4889US10378038B2Mice that produce hybrid antibodiesREGENERON PHARMA·Filed 2013·Granted Aug 13, 2019·3 cites·3 claims
- 4989US10227625B2Methods of modifying eukaryotic cellsREGENERON PHARMA·Filed 2012·Granted Mar 12, 2019·3 cites·3 claims
- 5089US9655351B2Production of fertile XY female animals from XY ES cellsREGENERON PHARMA·Filed 2016·Granted May 23, 2017·3 cites·42 claims
Showing the top 50 of 119 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when David M. Valenzuela files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →